| Name | Title | Contact Details |
|---|
DBV Technologies (DBV) is a clinical-stage biopharmaceutical company focused on discovering safe and effective treatments for patients with food allergies and other unmet medical needs. DBV has developed a proprietary technology platform called Viaskin®, which is based on epicutaneous immunotherapy, or EPIT®, DBV`s method of delivering biologically active compounds to the immune system. This novel mechanism of action accesses the immune system through intact skin without allowing passage of the antigen into the bloodstream. The company is also exploring Viaskin® in other areas of unmet need including vaccines, inflammatory conditions and autoimmune diseases. DBV was founded in 2002 by Dr. Pierre-Henri Benhamou, Chairman and CEO, Dr. Christophe Dupont, Chairman of DBV`s Scientific Advisory Board, and Mr. Bertrand Dupont, Chief Technology Officer.
Taiga Biotechnologies is a privately-held developer of novel therapies for complex diseases including cancers, infectious agents such as HIV and influenza, and hematologic conditions.
FirstString Research was founded on a vision to deliver clinically relevant and effective solutions for the treatment of diseases based upon insights and understanding from the molecular and cellular contexts that define the underlying pathology.
Better products. Better service. MOLECULAR DESIGNS Molecular Designs is a team of doctors and scientists working to advance molecular diagnostics. We do this by developing, producing, and supplying multiplex assays for molecular testing ...
Two Pore Guys has created a digital, hand-held, single molecule biosensor that rivals the sensitivity of expensive medical lab equipment, yet is as inexpensive and easy to use as a blood glucose monitor.